Department of Oncology, Tampere University Hospital, Tampere, Finland.
Mol Imaging Biol. 2011 Aug;13(4):785-92. doi: 10.1007/s11307-010-0404-z.
The purpose of this study is to evaluate the time course of early chemotherapy response in patients with aggressive non-Hodgkin's lymphoma (NHL) by magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT).
Eight patients with histologically proven aggressive NHL were imaged by MRI and PET/CT before treatment (E1), 1 week (E2), and two cycles (E3) after chemotherapy.
The mean tumor volume on MRI was 276 mL at baseline; it decreased 58% at E2 (p < 0.05) and 65% further at E3 (p < 0.05), giving a total decrease of 84% (p < 0.05). All the imaged pre-therapy tumors were strongly positive on PET/CT, with a mean maximum standardized uptake value (SUV(max)) of 20. The SUV(max) decreased 60% at E2 (p < 0.05) and 59% further at E3 (p < 0.05), giving a total decrease of 83% (p < 0.05). The active tumor burden (mean 229 mL) decreased 66% at E2 (p < 0.05). The tumor volume on MRI correlated with the active tumor volume on fused PET/CT images in the same region of interest at both E1 and E2 (r = 0.88, p < 0.01, respectively).
Standard chemotherapy causes rapid decrease of both tumor metabolic activity and volume as early as 1 week, which continues to decline during therapy. Both volumetric MRI and PET/CT are valuable tools for early treatment response evaluation of aggressive NHL.
本研究旨在通过磁共振成像（MRI）和正电子发射断层扫描/计算机断层扫描（PET/CT）评估侵袭性非霍奇金淋巴瘤（NHL）患者的早期化疗反应时间过程。
8 例组织学证实为侵袭性 NHL 的患者在治疗前（E1）、1 周（E2）和两个周期（E3）后进行 MRI 和 PET/CT 成像。
基线时 MRI 上的平均肿瘤体积为 276mL；E2 时减少 58%（p<0.05），E3 时进一步减少 65%（p<0.05），总减少 84%（p<0.05）。所有治疗前的肿瘤在 PET/CT 上均呈强阳性，最大标准化摄取值（SUV(max)）平均为 20。E2 时 SUV(max)减少 60%（p<0.05），E3 时进一步减少 59%（p<0.05），总减少 83%（p<0.05）。活性肿瘤负担（平均 229mL）在 E2 时减少 66%（p<0.05）。MRI 上的肿瘤体积与同一感兴趣区融合 PET/CT 图像上的活性肿瘤体积在 E1 和 E2 时均相关（r=0.88，p<0.01）。
标准化疗可在 1 周内使肿瘤代谢活性和体积迅速下降，并在治疗过程中持续下降。MRI 体积和 PET/CT 都是评估侵袭性 NHL 早期治疗反应的有价值的工具。
